A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer. 1991

T Shinkai, and K Eguchi, and Y Sasaki, and T Tamura, and Y Ohe, and A Kojima, and F Oshita, and N Saijo
Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

This trial was carried out to evaluate the therapeutic benefit of the addition of mitomycin to vindesine plus cisplatin (80 mg/m2) in 126 previously untreated non-small cell lung cancer (NSCLC) patients. 124 patients were evaluable for toxicity and survival and 122 for response. No patient achieved complete response. The partial response rate (PR) in the vindesine plus cisplatin (VP) and mitomycin plus vindesine and cisplatin (MVP) groups were 23% (14/62) vs. 35% (21/60) (P = 0.13) with a median duration of response of 23 vs. 37 weeks (P = 0.071), respectively. Time to progression (TTP) and survival time (ST) were similar for both treatment arms [median TTP; 14 vs. 21 weeks (P = 0.10), median ST; 9.1 vs. 10.5 months (P = 0.94), respectively]. No difference in the frequency of side-effects was observed except that WHO grade 3 and 4 leukopenia was higher in the MVP group. In multivariate analysis, the significant predictors of survival were serum albumin, sex, performance status, lactate dehydrogenase and stage. In conclusion, the addition of mitomycin to the VP regimen appears to have limited value in advanced NSCLC.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008937 Mitomycins A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005260 Female Females

Related Publications

T Shinkai, and K Eguchi, and Y Sasaki, and T Tamura, and Y Ohe, and A Kojima, and F Oshita, and N Saijo
March 1996, Respirology (Carlton, Vic.),
T Shinkai, and K Eguchi, and Y Sasaki, and T Tamura, and Y Ohe, and A Kojima, and F Oshita, and N Saijo
July 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T Shinkai, and K Eguchi, and Y Sasaki, and T Tamura, and Y Ohe, and A Kojima, and F Oshita, and N Saijo
September 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
T Shinkai, and K Eguchi, and Y Sasaki, and T Tamura, and Y Ohe, and A Kojima, and F Oshita, and N Saijo
April 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T Shinkai, and K Eguchi, and Y Sasaki, and T Tamura, and Y Ohe, and A Kojima, and F Oshita, and N Saijo
October 1991, American journal of clinical oncology,
T Shinkai, and K Eguchi, and Y Sasaki, and T Tamura, and Y Ohe, and A Kojima, and F Oshita, and N Saijo
April 1990, British journal of cancer,
T Shinkai, and K Eguchi, and Y Sasaki, and T Tamura, and Y Ohe, and A Kojima, and F Oshita, and N Saijo
January 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
T Shinkai, and K Eguchi, and Y Sasaki, and T Tamura, and Y Ohe, and A Kojima, and F Oshita, and N Saijo
February 1996, Lung cancer (Amsterdam, Netherlands),
T Shinkai, and K Eguchi, and Y Sasaki, and T Tamura, and Y Ohe, and A Kojima, and F Oshita, and N Saijo
October 1996, Annals of oncology : official journal of the European Society for Medical Oncology,
T Shinkai, and K Eguchi, and Y Sasaki, and T Tamura, and Y Ohe, and A Kojima, and F Oshita, and N Saijo
June 2003, Zhongguo fei ai za zhi = Chinese journal of lung cancer,
Copied contents to your clipboard!